COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,549 Articles (22,400 medRxiv, 8,149 bioRxiv)

Most recent first Previous |  Page 711: Articles 7101-7110  | Next

The ATLAS™ screening assay reveals distinct CD4+ and CD8+ SARS-CoV-2 antigen response profiles which have implications to Omicron cellular immunity
Foti, J. J., Lema, K., Strickland, J., Tjon, E., Li, A., Rivera, A., Cabral, C., Cormier, L., Dowal, L., Rao, S., Vemulapalli, V., Flechtner, J. B.
10.1101/2022.05.17.491668 — Posted: 2022-05-17
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the Omicron wave
Al Jurdi, A., Morena, L., Cote, M., Bethea, E., Azzi, J., Riella, L. V.
10.1101/2022.05.17.22274980 — Posted: 2022-05-17
Unsupervised outlier detection applied to SARS-CoV-2 nucleotide sequences can identify sequences of common variants and other variants of interest
Hahn, G., Lee, S., Prokopenko, D., Abraham, J., Novak, T., Hecker, J., Cho, M., Khurana, S., Baden, L. R., Randolph, A. G., Weiss, S. T., Lange, C.
10.1101/2022.05.16.492178 — Posted: 2022-05-17
Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
Qu, P., Evans, J. P., Faraone, J. N., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Mohler, P. J., Gumina, R. J., Liu, S.-L.
10.1101/2022.05.16.492158 — Posted: 2022-05-17
Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis.
Rizvi, Z. A., Babele, P., Sadhu, S., Madan, U., Tripathy, M. R., Goswami, S., Mani, S., Kumar, S., Awasthi, A., Dikshit, M.
10.1101/2022.05.16.492112 — Posted: 2022-05-17
Racial differences in vaccine acceptance in a rural southern US state
Amick, B. C., Allen, J. L., Brown, C. C., Goudie, A., Tilford, M., Williams, M.
10.1101/2022.05.12.22274953 — Posted: 2022-05-17
Neuropathic symptoms with SARS-CoV-2 vaccination
Safavi, F., Gustafson, L., Walitt, B., Lehky, T., Dehbashi, S., Wiebold, A., Mina, Y., Shin, S., Pan, B., Polydefkis, M., Oaklander, A. L., Nath, A.
10.1101/2022.05.16.22274439 — Posted: 2022-05-17
A live attenuated vaccine confers superior mucosal and systemic immunity to SARS-CoV-2 variants
Nouailles, G., Adler, J. M., Pennitz, P., Peidli, S., Teixeira Alves, G., Baumgart, M., Bushe, J., Voss, A., Langenhagen, A., Pott, F., Kazmierski, J., Goekeri, C., Simmons, S., Xing, N., Langner, C., Martin Vidal, R., Abdelgawad, A., Herwig, S., Cichon, G., Niemeyer, D., Drosten, C., Goffinet, C., Landthaler, M., Blüthgen, N., Wu, H., Witzenrath, M., Gruber, A. D., Praktiknjo, S. D., Osterrieder, N., Wyler, E., Kunec, D., Trimpert, J.
10.1101/2022.05.16.492138 — Posted: 2022-05-16
Summaries, Analysis and Simulations of Recent COVID-19 Epidemic in Shanghai
Min, L.
10.1101/2022.05.15.22273842 — Posted: 2022-05-16
Quantifying the information in noisy epidemic curves
Parag, K. V., Donnelly, C. A., Zarebski, A. E.
10.1101/2022.05.16.22275147 — Posted: 2022-05-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).